Wall Street brokerages forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will announce earnings per share (EPS) of ($0.39) for the current quarter, Zacks reports. Four analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.28). Tetraphase Pharmaceuticals reported earnings of ($0.42) per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.1%. The firm is expected to announce its next earnings results on Thursday, May 2nd.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.52) per share for the current year, with EPS estimates ranging from ($1.78) to ($1.23). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.08) per share, with EPS estimates ranging from ($1.68) to ($0.71). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.40). The firm had revenue of $4.28 million during the quarter, compared to analyst estimates of $2.23 million. Tetraphase Pharmaceuticals had a negative net margin of 381.71% and a negative return on equity of 72.26%.
NASDAQ:TTPH traded up $0.14 on Friday, reaching $1.34. 1,266,539 shares of the company’s stock were exchanged, compared to its average volume of 679,173. The company has a quick ratio of 7.73, a current ratio of 7.78 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $64.49 million, a PE ratio of -0.98 and a beta of 2.99. Tetraphase Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $4.49.
Several hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Tetraphase Pharmaceuticals by 6.4% in the fourth quarter. Bank of America Corp DE now owns 142,775 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 8,567 shares during the period. Gamco Investors INC. ET AL boosted its position in shares of Tetraphase Pharmaceuticals by 42.9% in the fourth quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 15,000 shares during the period. Rhumbline Advisers boosted its position in shares of Tetraphase Pharmaceuticals by 40.6% in the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 21,089 shares during the period. Geode Capital Management LLC boosted its position in shares of Tetraphase Pharmaceuticals by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 551,837 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 21,854 shares during the period. Finally, Alambic Investment Management L.P. raised its stake in Tetraphase Pharmaceuticals by 31.0% in the fourth quarter. Alambic Investment Management L.P. now owns 114,874 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 27,170 shares in the last quarter. Institutional investors own 44.02% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Recommended Story: How is Preferred Stock Different from Common Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.